[1] MIYAZAWA Y,YOKOHAMA A,ISHIZAKI T,et al.Pathological and molecular analysis of a composite lymphoma of mantle cell lymphoma and Epstein-Barr virus-positive follicular lymphoma[J].Int J Hematol,2021,113(4):592-599.
[2] KIM H N,JEON M J,YU E S,et al.Composite follicular lymphoma and classic Hodgkin lymphoma[J].J Pathol Transl Med,2022,56(1):57-60.
[3] 郭亮,白晶,姚伟凯,等.组合性套细胞淋巴瘤合并经典型霍奇金淋巴瘤一例[J].中华病理学杂志,2019,48(5):409-410.
[4] 夏钰弘,杨国仪,侯刚,等.前纵隔组合性淋巴瘤1例[J]. 临床与实验病理学杂志,2015,31(1):108-109.
[5] NIINO D,MY HANH L T,MIURA S,et al.Incidence patterns of sequential or composite lymphoma:a population-based cancer registry study[J].Tohoku J Exp Med,2021,254(2):123-127.
[6] RICCI C,AMBROSI F,AGOSTINELLI C,et al.Cutaneous composite lymphoma consisting of chronic lymphocytic leukemia/small lymphocytic lymphoma and follicular lymphoma:a unique entity and a putative pathological mechanism for cutaneous composite lymphomas[J]. Ital J Dermatol Venerol,2021,156(Suppl. 1 to No. 6):18-19.
[7] SHEN J,WANG J S,XIE J L,et al.Hemophagocytic lymphohistiocytosis secondary to composite lymphoma:two case reports[J].World J Clin Cases,2021,9(30):9159-9167.
[8] WANG J,ZHANG R Z.Composite lymphoma of cervical lymph nodes with classical Hodgkin lymphoma and diffuse large B cell lymphoma:a case report and literature review[J].Ann Palliat Med,2020,9(5):3651-3662.
[9] MASS J,ALOBEID B.Composite mantle cell lympho ma and small lymphocytic lymphoma in a lymph node[J]. Blood,2021,137(2):282.
[10] TRIMECH M,LETOURNEAU A,MISSIAGLIA E,et al.Angioimmunoblastic T-cell lymphoma and chronic lymphocytic leukemia/small lymphocytic lymphoma:a novel form of composite lymphoma potentially mimicking Richter syndrome[J]. Am J Surg Pathol,2021,45(6):773-786.
[11] VIVIAN L F,MAGNOLI F,CAMPIOTTI L,et al.Composite follicular lymphoma and “early” (in situ and mantle zone growth pattern) mantle cell neoplasia:a rare entity with peculiar cytogenetic and clinical features[J]. Pathol Res Pract,2020,216(9):153067.
[12] MAESHIMA A M,TANIGUCHI H,NOMOTO J,et al.Clinicopathological features of classical Hodgkin lymphoma in patients≥40 years old,with special reference to composite cases[J]. Jpn J Clin Oncol,2015,45(10):921-928.
[13] SABATER-MARCO V,SANTONJA-LÓPEZ N,ORTÍZ-ZULUAGA S,et al. Orbital soft tissue composite lymphoma presenting as recurrence of a nodal lymphoma with mantle and follicular cell components:a case report,literature review and guideline for the treatment of patients[J]. Rev Esp Patol,2020,53(1):48-54.
[14] AUSSEDAT G,TRAVERSE-GLEHEN A,STAMATOULLAS A,et al.Composite and sequential lymphoma between classical Hodgkin lymphoma and primary mediastinal lymphoma/diffuse large B-cell lymphoma,a clinico-pathological series of 25 cases[J]. Br J Haematol,2020,189(2):244-256.
[15] CHEN Y D,NONG L,LI X,et al.Cutaneous composite lymphoma of mycosis fungoides and Hodgkin lymphoma:response to sequential therapy[J]. J Cutan Pathol,2020,47(9):829-833.
[16] GUI W,WANG J,MA L,et al.Clinicopathological analysis of composite lymphoma:a two-case report and literature review[J].Open Med (Wars),2020,15(1):654-658.
[17] FAIRCHILD A,MCCALL C M,OYEKUNLE T,et al.Primary mediastinal (thymic) large B-cell lymphoma:fidelity of diagnosis using WHO criteria[J]. Clin Lymphoma Myeloma Leuk,2021,21(5):e464-e469.
[18] GONZÁLEZ-GASCÓN Y MARÍN I,MENARGUEZ J,KWON M,et al. Composite lymphoma containing mantle cell and peripheral T-cell lymphoma,not otherwise specified:a report of 2 cases treated with up-front autologous stem cell transplantation[J].Appl Immunohistochem Mol Morphol,2020,28(10):e94-e98.
[19] SHAH N N,SZABO A,HUNTINGTON S F,et al.R-CHOP versus dose-adjusted R-EPOCH in frontline management of primary mediastinal B-cell lymphoma:a multi-centre analysis[J]. Br J Haematol,2018,180(4):534-544.
[20] ZINZANI P L,SANTORO A,GRITTI G,et al.Nivolumab combined with brentuximab vedotin for relapsed/refractory primary mediastinal large B-cell lymphoma:efficacy and safety from the phase II CheckMate 436 study[J].J Clin Oncol,2019,37(33):3081-3089.
[21] ANSELL S M.Hodgkin lymphoma:a 2020 update on diagnosis,risk-stratification,and management[J].Am J Hematol,2020,95(8):978-989.
[22] CAMUS V,BIGENWALD C,RIBRAG V,et al.Pembrolizumab in the treatment of refractory primary mediastinal large B-cell lymphoma:safety and efficacy[J].Expert Rev Anticancer Ther,2021,21(9):941-956.
[23] 楚海亮,张司琪,李淑娥,等. PD-1抑制剂联合GVD化疗成功治疗复发/难治性原发性纵隔大B细胞淋巴瘤1例[J]. 临床输血与检验,2022,24(1):112-117. |
